Alvotech (NASDAQ:ALVO) Faces Securities Claims After 34% Stock Drop Due to Misleading Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: PRnewswire
- Stock Price Plunge: Alvotech's stock plummeted 34% on November 3, 2025, following allegations of issuing misleading business information, with an additional nearly 4% drop the next day, severely undermining investor confidence.
- Legal Action Initiated: The Rosen Law Firm is investigating potential securities claims on behalf of Alvotech shareholders and is preparing a class action to seek compensation for investor losses without any upfront fees.
- FDA Response: On November 2, 2025, Alvotech announced that the FDA issued a complete response letter regarding its Biologics License Application, citing deficiencies found during an inspection of its Reykjavik facility, which must be resolved before approval can be granted.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and expertise in the field of securities litigation.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 8.60 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 5.290
Low
5.00
Averages
8.60
High
10.00
Current: 5.290
Low
5.00
Averages
8.60
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Reaches Licensing Settlement with Regeneron and Bayer
- Patent Dispute Resolution: Alvotech has reached a settlement with Regeneron and Bayer, resolving all global patent disputes related to its Eylea® biosimilar, thereby securing its rights to manufacture and supply in the global market, which enhances its market position in biopharmaceuticals.
- Market Access Timeline: The agreement allows Alvotech's Eylea biosimilar to launch in the UK and Canada on January 1, 2026, and in the European Economic Area on May 1, 2026, marking a significant expansion and revenue growth potential for the company.
- Commercial Partner Network: Alvotech's commercial partners in Europe include Advanz Pharma, STADA, and Biogaran, which will facilitate the successful launch of its biosimilar, further solidifying its position in a competitive market.
- Long-term Sustainability: CEO Robert Wessman stated that resolving patent issues will support collaboration with commercial partners, promoting the sustainability of global healthcare systems, indicating the company's confidence in future market opportunities.
Continue Reading
Alvotech Settles Patent Disputes with Regeneron and Bayer
- Global Patent Settlement: Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes related to its Eylea biosimilar, thereby ensuring its legitimacy and competitiveness in global markets.
- Market Entry Timeline: Under the agreement, Alvotech will launch the biosimilar in the UK and Canada starting January 1, 2026, and in the EEA and other countries (excluding the U.S.) and Japan (excluding DME) from May 1, 2026, significantly expanding its market reach.
- U.S. Market Outlook: Alvotech has secured a Q4 2026 license entry date for the U.S. market, pending regulatory approval, which lays a foundation for future revenue growth and reflects its strategic positioning in the biopharmaceutical sector.
- Confidential Terms Impact: While the remaining terms of the agreement remain confidential, the settlement provides a stable market environment for Alvotech and its commercial partners, enhancing their competitive advantage in the biosimilar market.
Continue Reading